Aethlon medical announces financial results for the fiscal second quarter ended september 30, 2024 and provides corporate update

Achieves key milestone with enrollment of first two patients in the safety, feasibility, and dose finding study of aethlon's hemopurifier® in patients with solid tumors not responding to anti-pd-1 antibodies two australian sites open for patient enrollment in hemopurifier® cancer trial conference call to be held today at 4:30 p.m. et san diego , nov. 13, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended september 30, 2024 and provided an update on recent developments.
AEMD Ratings Summary
AEMD Quant Ranking